SURROZEN INC
SRZN · NASDAQ
Updated at 2026-10-14 09:03:13
- Today's High
- $24.37
- Today’s Low
- $21.85
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $28.70
- Previous Close
- $24.76
- Volume
- 1.52M
- Market Cap
- $291.01M
- P/E Ratio
- --
- EPS
- $-35.78
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080
- Country
- US
- Listing Date
- 2020-11-23
- Fiscal Year End
- December
- Shares Outstanding
- 11.61M
- CIK
- 0001824893
- Website
- www.surrozen.com
Surrozen Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapeutics using its proprietary SIRPa-IgG platform, which is designed to modulate targeted immune responses. The company's promising pipeline includes novel antibody therapeutics aimed at treating serious oncological and autoimmune disorders, addressing critical unmet medical needs. With a strong focus on research and development, coupled with strategic partnerships, Surrozen is well-positioned to deliver transformative therapies, offering significant potential for growth and a meaningful impact within the biopharmaceutical landscape.
Financial Metrics
Revenue
2026-06-30
$5M
2026-03-31
$5M
2025-12-31
$528K
2025-09-30
$983K
Operating Expenses
2026-06-30
$15.37M
2026-03-31
$15.39M
2025-12-31
$13.16M
2025-09-30
$11.86M
Net Income
2026-06-30
$50.17M
2026-03-31
-$127.5M
2025-12-31
-$183.15M
2025-09-30
-$71.64M
Net Profit Margin
2026-06-30
1K%
2026-03-31
-2.55K%
2025-12-31
-34.68K%
2025-09-30
-7.28K%
Earnings Per Share
2026-06-30
$-0.41
2026-03-31
$-4.63
2025-12-31
$-9.61
2025-09-30
$-3.60
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
$50.17M
2026-03-31
-$127.44M
2025-12-31
-$183.11M
2025-09-30
-$71.58M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $5M | $5M | $528K | $983K |
| Operating Expenses | $15.37M | $15.39M | $13.16M | $11.86M |
| Net Income | $50.17M | -$127.5M | -$183.15M | -$71.64M |
| Net Profit Margin | 1K% | -2.55K% | -34.68K% | -7.28K% |
| Earnings Per Share | $-0.41 | $-4.63 | $-9.61 | $-3.60 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | $50.17M | -$127.44M | -$183.11M | -$71.58M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.